Reminder of Class Action Lawsuit for ADMA Biologics Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that the deadline to file a lead plaintiff motion in the class action against ADMA Biologics is August 10, 2026, for those who purchased securities between August 9, 2024, and March 25, 2026.
- Allegations: A report by Culper Research alleges that ADMA engaged in channel stuffing to artificially inflate revenue and failed to disclose related party transactions, misleading investors about the company's operations.
- Stock Price Impact: Following the report, ADMA's stock price fell by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, which significantly harmed investors' financial interests.
- Legal Implications: The lawsuit claims that ADMA made materially false statements throughout the class period and failed to disclose adverse facts about its business and prospects, potentially leading to greater financial losses for investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Class Action Lawsuit Reminder
- Via Transportation Class Action: A class action lawsuit against Via Transportation, Inc. (NYSE:VIA) alleges that from September 2025 to June 2026, the company failed to disclose a decline in annual recurring revenue per customer and regulatory issues, misleading investors about its business prospects, with a lead plaintiff deadline of August 10, 2026.
- Zillow Legal Risks: Zillow Group, Inc. (NASDAQ:Z,ZG) faces a class action lawsuit for the period from February 2025 to May 2026, accused of misrepresenting its agreement with Redfin as a partnership rather than an acquisition, and downplaying legal exposure amid antitrust scrutiny, requiring investor action by August 10, 2026.
- ADMA Biologics Issues: ADMA Biologics, Inc. (NASDAQ:ADMA) is implicated in a class action from August 2024 to March 2026 for failing to disclose related party transactions and revenue inflation tactics, lacking adequate internal controls, misleading investors about its operations, with a lead plaintiff deadline of August 10, 2026.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors that participation in these class actions does not require immediate action, allowing investors to retain counsel of their choice or remain absent while ensuring their rights are protected.
See More
Reminder of Class Action Lawsuit for ADMA Biologics Investors
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that the deadline to file a lead plaintiff motion in the class action against ADMA Biologics is August 10, 2026, for those who purchased securities between August 9, 2024, and March 25, 2026.
- Allegations: A report by Culper Research alleges that ADMA engaged in channel stuffing to artificially inflate revenue and failed to disclose related party transactions, misleading investors about the company's operations.
- Stock Price Impact: Following the report, ADMA's stock price fell by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, which significantly harmed investors' financial interests.
- Legal Implications: The lawsuit claims that ADMA made materially false statements throughout the class period and failed to disclose adverse facts about its business and prospects, potentially leading to greater financial losses for investors.
See More
ADMA Biologics Accused of Concealing Financial Risks
- Disclosure Controversy: ADMA Biologics allegedly used vague risk language in seven SEC filings from August 2024 to March 2026, claiming its internal controls could not provide absolute assurance, thereby obscuring the fictitious nature of its reported 20% ASCENIV revenue growth, which was actually a 3% decline driven by channel stuffing.
- Related Party Transaction Issues: The company disclosed related party transactions with GenesisBPS, owned by the Grossman family, reporting amounts ranging from $34,000 to $400,000 per period, yet the repetitive nature of these disclosures failed to reveal their significant impact on financial health, potentially misleading investors about the company's true financial status.
- Legal Liability Risks: The lawsuit highlights that ADMA's generic risk warnings do not shield it from liability when specific issues are already occurring, as investors are entitled to know about related party sales and their impact on revenue growth, which could expose the company to severe legal consequences.
- Investor Action Recommendations: Affected investors are advised to gather purchase records and contact SueWallSt for a free evaluation to ensure they can participate in claims and recover losses incurred due to ADMA's alleged disclosure failures before the lead plaintiff deadline of August 10, 2026.
See More
ADMA Biologics Faces Class Action Over Alleged Channel Stuffing
- Lawsuit Background: Berger Montague PC has filed a class action lawsuit against ADMA Biologics, alleging that the company engaged in channel stuffing from August 9, 2024, to March 25, 2026, in an attempt to drive revenue growth amid declining demand for ASCENIV, which undermines investor confidence.
- Financial Manipulation Allegations: According to a report by Culper Research, ADMA allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, resulting in a reported 20% revenue growth in 2025 that was not genuine; without this scheme, the company would have faced a 3% revenue decline.
- Stock Price Reaction: Following the lawsuit announcement, ADMA's stock price plummeted from $13.59 on March 23, 2026, to $11.33, a 16% drop, and fell another 15% to $9.63 the next day, reflecting market concerns over the company's financial transparency.
- Investor Action: Investors must apply by August 10, 2026, to be appointed as lead plaintiffs in the class action, highlighting concerns over corporate governance and financial reporting that could impact future investment decisions and the company's reputation.
See More
Class Action Lawsuit Filed Against ADMA Biologics
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against ADMA Biologics in the U.S. District Court for New Jersey on behalf of investors who purchased securities between August 9, 2024, and March 25, 2026, indicating significant legal risks for the company.
- Detailed Allegations: The lawsuit alleges that ADMA failed to disclose related party transactions, engaged in channel stuffing to inflate revenue, and lacked adequate internal controls, potentially misleading investors about the company's financial health and impacting their investment decisions.
- Stock Price Volatility: Following the release of a short report by Culper Research, ADMA's stock price fell by $2.26, or 16.63%, to close at $11.33 per share on March 24, 2026, reflecting market concerns regarding the company's financial stability.
- Investor Action Encouraged: The law firm urges investors who suffered losses during the class period to reach out for legal support, demonstrating the firm's commitment to protecting investor rights and providing assistance in navigating the legal process.
See More
Securities Fraud Class Action Filed Against ADMA Biologics
- Lawsuit Background: A class action lawsuit has been filed against ADMA Biologics (NASDAQ: ADMA) for securities fraud, alleging significant misstatements and omissions in financial reporting during the period from August 9, 2024, to March 25, 2026, which undermines investor confidence.
- Key Allegations: The lawsuit claims that ADMA engaged in undisclosed related party transactions and used channel stuffing to inflate revenues, lacking adequate internal controls, which rendered the company's positive business outlook misleading and potentially harmful to investors.
- Stock Price Reaction: Following a report by Culper Research on March 24, 2026, alleging channel stuffing, ADMA's stock price plummeted by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, indicating severe market concerns regarding the company's financial health.
- Investor Action: Affected investors must file for lead plaintiff status by August 10, 2026, to represent other investors in the lawsuit, with KTMC offering free case evaluations, emphasizing that there are no costs involved for investors during this process.
See More
Investor Class Action Lawsuit Reminder
- Via Transportation Class Action: A class action lawsuit against Via Transportation, Inc. (NYSE:VIA) alleges that from September 2025 to June 2026, the company failed to disclose a decline in annual recurring revenue per customer and regulatory issues, misleading investors about its business prospects, with a lead plaintiff deadline of August 10, 2026.
- Zillow Legal Risks: Zillow Group, Inc. (NASDAQ:Z,ZG) faces a class action lawsuit for the period from February 2025 to May 2026, accused of misrepresenting its agreement with Redfin as a partnership rather than an acquisition, and downplaying legal exposure amid antitrust scrutiny, requiring investor action by August 10, 2026.
- ADMA Biologics Issues: ADMA Biologics, Inc. (NASDAQ:ADMA) is implicated in a class action from August 2024 to March 2026 for failing to disclose related party transactions and revenue inflation tactics, lacking adequate internal controls, misleading investors about its operations, with a lead plaintiff deadline of August 10, 2026.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors that participation in these class actions does not require immediate action, allowing investors to retain counsel of their choice or remain absent while ensuring their rights are protected.
See More
Reminder of Class Action Lawsuit for ADMA Biologics Investors
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that the deadline to file a lead plaintiff motion in the class action against ADMA Biologics is August 10, 2026, for those who purchased securities between August 9, 2024, and March 25, 2026.
- Allegations: A report by Culper Research alleges that ADMA engaged in channel stuffing to artificially inflate revenue and failed to disclose related party transactions, misleading investors about the company's operations.
- Stock Price Impact: Following the report, ADMA's stock price fell by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, which significantly harmed investors' financial interests.
- Legal Implications: The lawsuit claims that ADMA made materially false statements throughout the class period and failed to disclose adverse facts about its business and prospects, potentially leading to greater financial losses for investors.
See More
ADMA Biologics Accused of Concealing Financial Risks
- Disclosure Controversy: ADMA Biologics allegedly used vague risk language in seven SEC filings from August 2024 to March 2026, claiming its internal controls could not provide absolute assurance, thereby obscuring the fictitious nature of its reported 20% ASCENIV revenue growth, which was actually a 3% decline driven by channel stuffing.
- Related Party Transaction Issues: The company disclosed related party transactions with GenesisBPS, owned by the Grossman family, reporting amounts ranging from $34,000 to $400,000 per period, yet the repetitive nature of these disclosures failed to reveal their significant impact on financial health, potentially misleading investors about the company's true financial status.
- Legal Liability Risks: The lawsuit highlights that ADMA's generic risk warnings do not shield it from liability when specific issues are already occurring, as investors are entitled to know about related party sales and their impact on revenue growth, which could expose the company to severe legal consequences.
- Investor Action Recommendations: Affected investors are advised to gather purchase records and contact SueWallSt for a free evaluation to ensure they can participate in claims and recover losses incurred due to ADMA's alleged disclosure failures before the lead plaintiff deadline of August 10, 2026.
See More
ADMA Biologics Faces Class Action Over Alleged Channel Stuffing
- Lawsuit Background: Berger Montague PC has filed a class action lawsuit against ADMA Biologics, alleging that the company engaged in channel stuffing from August 9, 2024, to March 25, 2026, in an attempt to drive revenue growth amid declining demand for ASCENIV, which undermines investor confidence.
- Financial Manipulation Allegations: According to a report by Culper Research, ADMA allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, resulting in a reported 20% revenue growth in 2025 that was not genuine; without this scheme, the company would have faced a 3% revenue decline.
- Stock Price Reaction: Following the lawsuit announcement, ADMA's stock price plummeted from $13.59 on March 23, 2026, to $11.33, a 16% drop, and fell another 15% to $9.63 the next day, reflecting market concerns over the company's financial transparency.
- Investor Action: Investors must apply by August 10, 2026, to be appointed as lead plaintiffs in the class action, highlighting concerns over corporate governance and financial reporting that could impact future investment decisions and the company's reputation.
See More
Class Action Lawsuit Filed Against ADMA Biologics
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against ADMA Biologics in the U.S. District Court for New Jersey on behalf of investors who purchased securities between August 9, 2024, and March 25, 2026, indicating significant legal risks for the company.
- Detailed Allegations: The lawsuit alleges that ADMA failed to disclose related party transactions, engaged in channel stuffing to inflate revenue, and lacked adequate internal controls, potentially misleading investors about the company's financial health and impacting their investment decisions.
- Stock Price Volatility: Following the release of a short report by Culper Research, ADMA's stock price fell by $2.26, or 16.63%, to close at $11.33 per share on March 24, 2026, reflecting market concerns regarding the company's financial stability.
- Investor Action Encouraged: The law firm urges investors who suffered losses during the class period to reach out for legal support, demonstrating the firm's commitment to protecting investor rights and providing assistance in navigating the legal process.
See More
Securities Fraud Class Action Filed Against ADMA Biologics
- Lawsuit Background: A class action lawsuit has been filed against ADMA Biologics (NASDAQ: ADMA) for securities fraud, alleging significant misstatements and omissions in financial reporting during the period from August 9, 2024, to March 25, 2026, which undermines investor confidence.
- Key Allegations: The lawsuit claims that ADMA engaged in undisclosed related party transactions and used channel stuffing to inflate revenues, lacking adequate internal controls, which rendered the company's positive business outlook misleading and potentially harmful to investors.
- Stock Price Reaction: Following a report by Culper Research on March 24, 2026, alleging channel stuffing, ADMA's stock price plummeted by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, indicating severe market concerns regarding the company's financial health.
- Investor Action: Affected investors must file for lead plaintiff status by August 10, 2026, to represent other investors in the lawsuit, with KTMC offering free case evaluations, emphasizing that there are no costs involved for investors during this process.
See More
